Innate T‐cell‐derived IL‐17A/F protects from bleomycin‐induced acute lung injury but not bleomycin or adenoviral TGF‐β1‐induced lung fibrosis in mice
European Journal of Immunology · 2024
DOI: 10.1002/eji.202451323 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Marie T Moog und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Pneumology, Clinic for Pneumology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Bleomycin, Interleukin-17, Pulmonary Fibrosis, Acute Lung Injury. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Federal Ministry of Education and Research, German Center for Lung Research, Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
The pathobiology of IL‐17 in lung fibrogenesis is controversial. Here we examined the role of IL‐17A/F in bleomycin (BLM) and adenoviral TGF‐β1‐induced lung fibrosis in mice. In both experimental models, WT and IL17af −/− mice showed increased collagen contents and remodeled lung architecture as assessed by histopathological examination, suggesting that IL‐17A/F is dispensable for lung fibrogenesis. However, IL17af −/− mice responded to the BLM challenge with perturbed lung leukocyte subset recruitment. More specifically, bleomycin triggered angiocentric neutrophilic infiltrations of the lung accompanied by increased mortality of IL17af −/− but not WT mice. WT bone marrow transplantation failed to correct this phenotype in BLM‐challenged IL17af −/− mice. Conversely, IL17a/f −/− bone marrow transplantation → WT did not perturb lung leukocytic responses upon BLM. At the same time, IL17af −/− mice treated with recombinant IL‐17A/F showed an attenuated lung inflammatory response to BLM. Together, the data show that the degree of BLM‐driven acute lung injury was critically dependent on the presence of IL‐17A/F, while in both models, the fibrotic remodeling process was not.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Experimental Pneumology, Clinic for Pneumology, Hannover Medical School, Hannover, Germany.
- Institute of Pathology, RWTH University Medical Center, Aachen, Germany.
- German Center for Lung Research, partner site BREATH, Hannover, Germany.
- Institute of Systems Immunology, University Medical Center Hamburg-Eppendorf, Germany.
- Department of Medicine, Pathology, and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Ulrich A Maus
Förderung
- Federal Ministry of Education and Research
- German Center for Lung Research
- Bundesministerium für Bildung und Forschung
- Deutsches Zentrum für Lungenforschung
Zitieren
APA
Moog, M. T., Baltes, M., Röpke, T., Aschenbrenner, F., Maus, R., Stolper, J., Jonigk, D., Prinz, I., Kolb, M., & Maus, U. A. (2024). Innate T‐cell‐derived IL‐17A/F protects from bleomycin‐induced acute lung injury but not bleomycin or adenoviral TGF‐β1‐induced lung fibrosis in mice. European Journal of Immunology. https://doi.org/10.1002/eji.202451323
Vancouver
Moog MT, Baltes M, Röpke T, Aschenbrenner F, Maus R, Stolper J, et al. Innate T‐cell‐derived IL‐17A/F protects from bleomycin‐induced acute lung injury but not bleomycin or adenoviral TGF‐β1‐induced lung fibrosis in mice. European Journal of Immunology. 2024. doi:10.1002/eji.202451323
BibTeX
@article{Moog2024,
author = {Moog, Marie T and Baltes, Melina and Röpke, Tina and Aschenbrenner, Franziska and Maus, Regina and Stolper, Jennifer and Jonigk, Danny and Prinz, Immo and Kolb, Martin and Maus, Ulrich A},
title = {Innate T‐cell‐derived IL‐17A/F protects from bleomycin‐induced acute lung injury but not bleomycin or adenoviral TGF‐β1‐induced lung fibrosis in mice},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202451323}
}
EUVIMED